GlassScriptPhysician profile
Mohammad M Chisti
NPI 1598911448
$179,686.86
in general payments reported to CMS, 2019-2025
36 companies · $3,683 in 2025
The $3,683 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $19K · 2021: $29K · 2022: $30K · 2023: $28K · 2024: $16K · 2025: $3,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $15K · Honoraria: $4,000 · Travel and Lodging: $3,820 · Food and Beverage: $2,271 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,600.00 |
| Consulting Fee | $14,900.50 |
| Honoraria | $4,000.00 |
| Travel and Lodging | $3,820.21 |
| Food and Beverage | $2,270.88 |
| Education | $187.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $133,646.37 | 2019-2024 | Verzenio |
| E.R. Squibb & Sons, L.L.C. | $18,443.60 | 2019-2024 | Opdivo, Augtyro |
| Astrazeneca Pharmaceuticals LP | $6,561.37 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| Incyte Corporation | $6,074.11 | 2022-2025 | |
| Immunogen, INC. | $5,949.22 | 2023 | Elahere |
| Deciphera Pharmaceuticals INC. | $4,197.50 | 2024 | Qinlock |
| Abbvie INC. | $1,800.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,370.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Eylea Hd |
| Tempus Ai, INC | $112.78 | 2024 | |
| Exelixis INC. | $107.10 | 2025 | Cabometyx |
| Medtronic, INC. | $50.52 | 2023 | Ligasure |
| Genzyme Corporation | $44.18 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $39.11 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endomagnetics LTD | $37.94 | 2023 | Magseed, Magtrace |
| Glaxosmithkline, LLC. | $37.64 | 2025 | Ojjaara |
| Astellas Pharma US INC | $35.78 | 2023-2025 | Padcev, Xospata |
| Gilead Sciences, INC. | $33.85 | 2021-2024 | |
| Emmaus Medical, INC. | $33.23 | 2024 | Endari |
| Jazz Pharmaceuticals INC. | $31.72 | 2024 | |
| Pfizer INC. | $28.93 | 2019-2023 | |
| Beigene USA, INC. | $25.95 | 2023 | Brukinsa |
| Celgene Corporation | $23.21 | 2023 | Reblozyl |
| Amgen INC. | $22.74 | 2023 | Nplate, Xgeva, Vectibix |
| Puma Biotechnology, INC. | $22.59 | 2025 | |
| Genentech USA, INC. | $21.75 | 2025 | Polivy |
| Pharmacyclics LLC, An Abbvie Company | $21.49 | 2023 | Imbruvica |
| Azurity Pharmaceuticals, INC. | $20.78 | 2024 | Vivimusta |
| Recordati_rare_diseases_inc. | $18.24 | 2024 | Sylvant |
| Blueprint Medicines Corporation | $18.14 | 2024 | Ayvakit |
| Mirati Therapeutics, INC. | $17.75 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $17.50 | 2023 | Keytruda |
| Acrotech Biopharma INC. | $16.85 | 2023 | Beleodaq |
| Myriad Genetic Laboratories, INC. | $15.85 | 2024 | Myrisk |
| Sobi, INC | $14.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Chisti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.